title: Whole abdominal radiotherapy following cytoreductive surgery and chemotherapy in ovarian carcinoma.
abstract: Persistent or recurrent disease following surgery and chemotherapy in ovarian carcinoma remains a major therapeutic dilemma. Between January 1980 and December 1985, there were 26 patients who had previously undergone cytoreductive surgery and chemotherapy and were treated with external beam radiotherapy. Twenty-one of these patients had been treated with platinum-adriamycin-cytoxan (PAC) regimen and 5 were treated with other combinations. Surgical reevaluation was performed in 21 of the 26 patients and only 4/21 (19%) patients were free of disease. All 26 patients were irradiated with a planned dose of 2500 cGy/100 cGy/day or 2280 cGy/120 cGy/day to the whole abdomen and a final calculated dose to the pelvis of 4500 cGy. Initial evaluation showed a 3-year actuarial survival rate of 51% and a disease-free survival rate of 42%. Follow-up analysis yields survivals of 45 and 35%, respectively. Severe gastrointestinal complications were observed in 3/26 patients and all hematologic complications resolved. Variables of prognostic significance were chemotherapy tolerance, grade, and volume of residual disease. We conclude that a proportion of patients with disease following cytoreductive surgery and chemotherapy may be salvaged with abdominopelvic irradiation.
authors.affiliation: Division of Therapeutic Radiology and Oncology, University of Virginia Medical Center, Charlottesville 22908.
authors.forename: C R
authors.initials: CR
authors.lastname: Kersh
authors.forename: M E
authors.initials: ME
authors.lastname: Randall
authors.forename: W C
authors.initials: WC
authors.lastname: Constable
authors.forename: S S
authors.initials: SS
authors.lastname: Hahn
authors.forename: P T
authors.initials: PT
authors.lastname: Taylor
authors.forename: H B
authors.initials: HB
authors.lastname: Krebs
authors.forename: D R
authors.initials: DR
authors.lastname: Goplerud
mesh_terms: D000005:Abdomen; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy / Q000532:radiotherapy* / Q000601:surgery; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008875:Middle Aged; D009026:Mortality; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000532:radiotherapy* / Q000601:surgery; D011379:Prognosis; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents